BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 32756527)

  • 1. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
    Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
    Chang TC; Chin YT; Nana AW; Wang SH; Liao YM; Chen YR; Shih YJ; Changou CA; Yang YS; Wang K; Whang-Peng J; Wang LS; Stain SC; Shih A; Lin HY; Wu CH; Davis PJ
    Horm Cancer; 2018 Dec; 9(6):420-432. PubMed ID: 30187356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for proliferation in oral cancer cells.
    Lin SJ; Chin YT; Ho Y; Chou SY; Sh Yang YC; Nana AW; Su KW; Lim YT; Wang K; Lee SY; Shih YJ; Chen YR; Whang-Peng J; Davis PJ; Lin HY; Fu E
    Food Chem Toxicol; 2018 Oct; 120():1-11. PubMed ID: 29960019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status.
    Lee YS; Chin YT; Yang YSH; Wei PL; Wu HC; Shih A; Lu YT; Pedersen JZ; Incerpi S; Liu LF; Lin HY; Davis PJ
    Steroids; 2016 Jul; 111():63-70. PubMed ID: 26980146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
    Lin HY; Chin YT; Nana AW; Shih YJ; Lai HY; Tang HY; Leinung M; Mousa SA; Davis PJ
    Steroids; 2016 Oct; 114():59-67. PubMed ID: 27221508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NDAT suppresses pro-inflammatory gene expression to enhance resveratrol-induced anti-proliferation in oral cancer cells.
    Ho Y; Wu CY; Chin YT; Li ZL; Pan YS; Huang TY; Su PY; Lee SY; Crawford DR; Su KW; Chiu HC; Shih YJ; Changou CA; Yang YSH; Whang-Peng J; Chen YR; Lin HY; Mousa SA; Davis PJ; Wang K
    Food Chem Toxicol; 2020 Feb; 136():111092. PubMed ID: 31883986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers.
    Nana AW; Wu SY; Yang YS; Chin YT; Cheng TM; Ho Y; Li WS; Liao YM; Chen YR; Shih YJ; Liu YR; Pedersen J; Incerpi S; Hercbergs A; Liu LF; Whang-Peng J; Davis PJ; Lin HY
    Horm Cancer; 2018 Oct; 9(5):349-360. PubMed ID: 30027502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
    Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
    Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
    Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
    Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
    Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells.
    Unson S; Chang TC; Yang YN; Wang SH; Huang CH; Crawford DR; Huang HM; Li ZL; Lin HY; Whang-Peng J; Wang K; Davis PJ; Li WS
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HNRNPL affects the proliferation and apoptosis of colorectal cancer cells by regulating PD-L1.
    Zhao Y; Wang Y; Wang Q
    Pathol Res Pract; 2021 Feb; 218():153320. PubMed ID: 33418347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
    Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
    Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
    J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.